Literature DB >> 15522069

Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome.

Simon D J Gibbs1, Kirsten E Herbert, Christopher McCormack, John F Seymour, H Miles Prince.   

Abstract

The simultaneous presentation of chronic lymphocytic leukaemia (CLL) and cutaneous T-cell lymphoma (CTCL) is a very rare occurrence where optimal treatment is unknown. We present the case of a 65-yr-old man who was successfully treated with alemtuzumab monotherapy for both disorders, but at a cost of severe infectious morbidity and prolonged pancytopenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522069     DOI: 10.1111/j.1600-0609.2004.00332.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  2 in total

1.  Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

Authors:  Rachael A Clark; Rei Watanabe; Jessica E Teague; Christoph Schlapbach; Marianne C Tawa; Natalie Adams; Andrew A Dorosario; Keri S Chaney; Corey S Cutler; Nicole R Leboeuf; Joi B Carter; David C Fisher; Thomas S Kupper
Journal:  Sci Transl Med       Date:  2012-01-18       Impact factor: 17.956

Review 2.  [Mycosis fungoides and B-cell chronic lymphocytic leukemia: an extremely rare coincidence].

Authors:  A Süss; T Wetzig; M Sticherling; A Tannapfel; J C Simon
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.